Salvage chemotherapy with docetaxel and pegylated liposomal doxorubicin in pretreated patients with platinum- and taxane-sensitive ovarian cancer: a multicenter phase II trial of the Hellenic Oncology Research Group (HORG)

Salvage Chemotherapy ◽

Oncology Research ◽

Multicenter Phase ◽

Pretreated Patients

Biweekly pegylated liposomal doxorubicin in patients with relapsed ovarian cancer: results of a multicenter phase-II trial

Annals of Oncology ◽

10.1093/annonc/mdl079 ◽

2006 ◽

Vol 17 (6) ◽

pp. 957-961 ◽

Cited By ~ 20

Author(s):

J. Sehouli ◽

G. Oskay-Özcelik ◽

J. Kühne ◽

D. Stengel ◽

H.-J. Hindenburg ◽

...

Keyword(s):

Ovarian Cancer ◽

Phase Ii ◽

Liposomal Doxorubicin ◽

Phase Ii Trial ◽

Multicenter Phase

Association of pegylated liposomal doxorubicin (PLD) and ifosfamide (IFO) in early recurrent ovarian cancer patients: A multicenter phase II trial

10.1200/jco.2005.23.16_suppl.5043 ◽

2005 ◽

Vol 23 (16_suppl) ◽

pp. 5043-5043 ◽

Cited By ~ 1

Author(s):

P. Chinet-Charrot ◽

F. Joly ◽

H. Bourgeois ◽

A. Lortholary ◽

B. Leduc ◽

...

Keyword(s):

Ovarian Cancer ◽

Cancer Patients ◽

Phase Ii ◽

Liposomal Doxorubicin ◽

Phase Ii Trial ◽

Recurrent Ovarian Cancer ◽

Multicenter Phase

Panitumumab and pegylated liposomal doxorubicin to platinum-resistant epithelial ovarian cancer with KRAS wild-type: An ongoing, nonrandomized, multicenter, phase II trial.

10.1200/jco.2010.28.15_suppl.tps254 ◽

2010 ◽

Vol 28 (15_suppl) ◽

pp. TPS254-TPS254 ◽

Cited By ~ 1

Author(s):

K. D. Steffensen ◽

M. Waldstr∅m ◽

B. Lund ◽

K. Bergfeldt ◽

N. Keldsen ◽

...

Keyword(s):

Ovarian Cancer ◽

Epithelial Ovarian Cancer ◽

Phase Ii ◽

Liposomal Doxorubicin ◽

Phase Ii Trial ◽

Wild Type ◽

Multicenter Phase ◽

Platinum Resistant

Association of pegylated liposomal doxorubicin and ifosfamide in early recurrent ovarian cancer patients: A Multicenter Phase II Trial

Gynecologic Oncology ◽

10.1016/j.ygyno.2009.09.036 ◽

2010 ◽

Vol 116 (3) ◽

pp. 312-316 ◽

Cited By ~ 4

Author(s):

Florence Joly ◽

Emmanuel Sevin ◽

Alain Lortholary ◽

Frank Priou ◽

J.F. Paitel ◽

...

Keyword(s):

Ovarian Cancer ◽

Cancer Patients ◽

Phase Ii ◽

Liposomal Doxorubicin ◽

Phase Ii Trial ◽

Recurrent Ovarian Cancer ◽

Multicenter Phase

Faculty Opinions recommendation of PRECEDENT: a randomized phase II trial comparing vintafolide (EC145) and pegylated liposomal doxorubicin (PLD) in combination versus PLD alone in patients with platinum-resistant ovarian cancer.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.718144304.793486590 ◽

2013 ◽

Author(s):

Roberto Angioli

Keyword(s):

Ovarian Cancer ◽

Phase Ii ◽

Liposomal Doxorubicin ◽

Phase Ii Trial ◽

Platinum Resistant ◽

Randomized Phase Ii

Phase II trial of pegylated liposomal doxorubicin (Caelyx™) plus Gemcitabine in chemotherapeutically pretreated patients with advanced breast cancer

Acta Oncologica ◽

10.1080/02841860600897868 ◽

2007 ◽

Vol 46 (2) ◽

pp. 208-213 ◽

Cited By ~ 7

Author(s):

Herbert Ulrich-Pur ◽

Gabriela V. Kornek ◽

Karin Haider ◽

Werner Kwasny ◽

Thomas Payrits ◽

...

Keyword(s):

Breast Cancer ◽

Advanced Breast Cancer ◽

Phase Ii ◽

Liposomal Doxorubicin ◽

Phase Ii Trial ◽

Advanced Breast ◽

Pretreated Patients

Pegylated liposomal doxorubicin and trastuzumab as 1st and 2nd line therapy in her2/neu positive metastatic breast cancer: a multicenter phase II trial

Breast Cancer Research and Treatment ◽

10.1007/s10549-008-0306-9 ◽

2009 ◽

Vol 117 (3) ◽

pp. 591-598 ◽

Cited By ~ 23

Author(s):

Elmar Stickeler ◽

Maximilian Klar ◽

Dirk Watermann ◽

Annette Geibel ◽

Martha Földi ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Phase Ii ◽

Liposomal Doxorubicin ◽

Phase Ii Trial ◽

Metastatic Breast ◽

Multicenter Phase ◽

Line Therapy

Phase II trial of carboplatin and distearoylphosphatidylcholine pegylated liposomal doxorubicin (Lipo-Dox®) in recurrent platinum-sensitive ovarian cancer following front-line therapy with paclitaxel and platinum

Gynecologic Oncology ◽

10.1016/j.ygyno.2008.09.033 ◽

2009 ◽

Vol 112 (1) ◽

pp. 35-39 ◽

Cited By ~ 13

Author(s):

Sheng-Mou Hsiao ◽

Chi-An Chen ◽

Ho-Hsiung Lin ◽

Chang-Yao Hsieh ◽

Lin-Hung Wei

Keyword(s):

Ovarian Cancer ◽

Phase Ii ◽

Liposomal Doxorubicin ◽

Phase Ii Trial ◽

Front Line ◽

Platinum Sensitive ◽

Line Therapy

Multicenter phase II trial of gemcitabine plus liposomal doxorubicin in chemotherapeutically pretreated patients with advanced breast cancer (ABC

10.1200/jco.2004.22.14_suppl.696 ◽

2004 ◽

Vol 22 (14_suppl) ◽

pp. 696-696

Author(s):

K. Haider ◽

G. Kornek ◽

W. Kwasny ◽

D. Depisch ◽

T. Payrits ◽

...

Keyword(s):

Breast Cancer ◽

Advanced Breast Cancer ◽

Phase Ii ◽

Liposomal Doxorubicin ◽

Phase Ii Trial ◽

Advanced Breast ◽

Multicenter Phase ◽

Pretreated Patients

Biweekly schedule of pegylated liposomal doxorubicin (PLD) induces low rates of skin toxicities: Results of a phase-II trial in heavily preteated patients with relapsed ovarian cancer

10.1200/jco.2004.22.14_suppl.5072 ◽

2004 ◽

Vol 22 (14_suppl) ◽

pp. 5072-5072 ◽

Cited By ~ 1

Author(s):

J. Sehouli ◽

G. Oskay ◽

I. Katsares ◽

P. Klare ◽

H. J. Hindenburg ◽

...

Keyword(s):

Ovarian Cancer ◽

Phase Ii ◽

Liposomal Doxorubicin ◽

Phase Ii Trial ◽

Pegylated Liposomal Doxorubicin